Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | IKBKB | O14920 | 15/20 | 0.53 |
| ▸ | LIMK1 | P53667 | 5/20 | 0.52 |
| ▸ | CHUK | O15111 | 1/20 | 0.52 |
| ▸ | PRKACA | P17612 | 1/20 | 0.52 |
| ▸ | PRKACG | P22612 | 1/20 | 0.52 |
| ▸ | PRKACB | P22694 | 1/20 | 0.52 |
| ▸ | BTK | Q06187 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2132343 | 0.87 | IKBKB (0.50) | IKBKBLIMK1CHUKPRKACAPRKACG | |
| SCHEMBL1176726 | 0.86 | IKBKB (0.49) | BRAFIKBKBLIMK1CHUKPRKACA | |
| SCHEMBL2130627 | 0.86 | IKBKB (0.49) | BRAFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL12871395 | 0.85 | IKBKB (0.50) | IKBKBLIMK1CHUKPRKACAPRKACG | |
| SCHEMBL1176502 | 0.84 | IKBKB (0.47) | BRAFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2134327 | 0.84 | IKBKB (0.47) | IKBKBLIMK1CHUKPRKACAPRKACG | |
| SCHEMBL1176328 | 0.83 | IKBKB (0.62) | IKBKBLIMK1CHUKPRKACAPRKACG | |
| SCHEMBL3414045 | 0.82 | TGFBR1 (0.37) | BRAFPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2133506 | 0.82 | IKBKB (0.54) | BRAFIKBKBLIMK1CHUKPRKACA | |
| SCHEMBL14281389 | 0.82 | BRAF (0.68) | BRAFPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102015724-A | Thienopyrimidines | MERCK PATENT GMBH | 2011-04-13 | — | — | CN | claimed |
| US-20110028472-A1 | THIENOPYRIMIDINES | MERCK PATENT CESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-03 | — | — | US | claimed |
| CN-102015724-A | Thienopyrimidines | MERCK PATENT GMBH | 2011-04-13 | — | — | CN | disclosed |
| US-20110028472-A1 | THIENOPYRIMIDINES | MERCK PATENT CESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-03 | — | — | US | disclosed |
| US-20110028472-A1 | THIENOPYRIMIDINES | MERCK PATENT CESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-03 | — | — | US | disclosed |
| US-20110028472-A1 | THIENOPYRIMIDINES | MERCK PATENT CESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028472-A1 | THIENOPYRIMIDINES | TGFBR1, TYMP, TGFBR2 | BRAF 183/4885PDE4A 1720/4885PDE4B 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.